

Antiviral Drugs

- Most infectious diseases in North America are caused by viruses
 - More than 95% of all respiratory disease
- All Class 4 pathogens are viruses
 - Ebola, Marburg, Lassa Fever, Hantavirus, Smallpox

Classification of Pathogens

- Class 1 - No risk or limited risk
 - Works on open lab bench
 - E. coli
 - P1 lab
 - P is level of protection
- Class 2 - Moderate Risk
 - Limited access to lab
 - Lab coat required
 - Laminar hoods provided
 - Herpes virus
 - P2 Lab
- Class 3 - Risk of death or serious illness
 - Restricted access, special training required
 - Surgical gowns, gloves, respirators
 - All liquids/air coming in/out is filtered/treated
 - Everything coming out is autoclaved and incinerated
 - HIV, Y. Pestis
 - P3
- Class 4 - Lethal, highly infectious, untreatable
 - Lab accessed by airlock, special training required
 - "Space suit" worn, shower going in or out
 - Low pressure in lab (leaks stay in), airlock
 - All liquids and gases filtered/treated going in and out
 - Ebola, Marburg, Lassa fever, Hantavirus, smallpox
 - P4 lab

Virus Structure

- All viruses categorized as having
 - Genetic information
 - DNA or RNA
 - Surrounded by a capsid
 - Hollow container made of protein
- Some viruses carry additional proteins
 - Enzymes
 - Regulatory proteins
- Some Viruses are Enveloped
 - Capsid is surrounded by a membrane
 - Remnant of the host cell membrane

- Contains viral proteins

Self-replicating Piece of Cellular Machinery

- Many viral proteins are structurally related to host proteins
 - Oncogenes
- Viral proteins often bind to host protein and alter that protein's function
 - Control cellular regulatory systems
- Common Elements (all viruses)
 - Duplications of genetic information
 - Productions of viral protein
- Viral processes utilize host proteins and machinery
 - Ribosome
 - Nucleic acid polymerases
- Viruses are not living

West Nile Virus

- 3 diff proteins in outside of structure
- 5 fold symmetry


Tobacco Mosaic Virus

- Red spiral - nucleic acid
- Blue spiral - protein


Difficulties in Developing Antiviral Drugs

- Each virus is unique
 - Each virus requires different drug
- Most viral proteins act by binding to host proteins
 - This is very difficult to target with drugs
 - Proteins tend to bind to each other very tightly
 - Utilize large contact surfaces
 - Creates tight binding between viruses
 - In order to break this tight bonding, we must develop a large drug which causes difficulties
 - Need to avoid interfering with normal host cells

Cell Signaling Systems use Protein Binding




Many Viral Proteins Operate by Binding to Host Proteins




- V - viral protein

Can Block Protein Binding in the Lab



Protein Binding is Difficult to Control with Drugs



Viral Enzymes as Drug Targets

- Viruses carry very few enzymes
 - Typical virus has 1 or 2
- Most involve nucleic acid replication
 - Host cells also make nucleic acids
 - Substrates, mechanisms, and structures are similar
- How do you block viral enzyme without blocking host enzyme?
 - Fundamental problem in dev. Antiviral drugs

Limited Number of Targets

- Most viruses have small genomes
 - As few as 10 genes
 - On average, 1 or 2 are enzymes
 - Most involve nucleic acids (host selectivity problem)

Today only a Few Good Antiviral Drugs Exist

- Hepatitis C (cure)
- Herpes (treat)

- HIV (manage)

Major Problems with Antiviral Drugs

- Selectivity
 - Kill virus without killing host
- Diagnosis
 - Drugs specific for each virus
 - Many viruses produce similar symptoms
 - More than 200 viruses cause colds
 - Only way to know for sure is biochemical test
- Resistance
 - Mutation rates in viruses very high
 - Viruses quickly develop resistance to drugs (days or weeks)

Immunization has been Very Successful for Viruses

- All time greatest achievement of medicine
 - Smallpox (disease eliminated)
 - Polio (Disease almost eliminated)
 - 1950 - hundreds of millions of cases (world)
 - 2018 (33 cases worldwide)
 - Measles
 - Mumps

Virus Life Cycle

- Absorption and penetration
 - Virus bind to host proteins on outside of host membrane
 - Capsid binds directly and is passed inside before opening
 - Envelope fuses with host cell membrane releasing capsid inside the cell
 - Genetic info is injected into the cell
 - Virus may also inject viral protein (enzyme or regulatory proteins)
 - Absorption and penetration are poor drug targets
 - Binding involves protein-protein interactions
 - Protein surface areas are very large
 - Difficult to inhibit protein-protein binding with small molecules
 - Limited success in HIV
 - Fuzeon - peptide with 36 amino acids
 - Maraviroc - small molecule
- Capsid Opens Releasing Contents
 - Release of viral nucleic acid
 - Capsid open releasing genetic information into the cell
 - Difficult to target
 - Protein interactions, pH changes
 - Two successful drugs
 - Influenza
 - Block an ion channel
- Synthesis of Regulatory Proteins

- Viral proteins are made
 - "Take over" normal cells systems
 - Nucleic acid replication
 - Expression of viral protein
 - Suppression of host cell defenses (apoptosis)
 - Binding to host proteins
 - No drugs currently exist for this phase
- Synthesis of RNA or DNA
 - Viral genome is replicated using host enzymes
 - Some viruses have their own enzymes for this (drug targets)
 - Most antiviral drugs target this phase
 - Require unique viral enzyme
 - Prevent viral nucleic acid synthesis
- Synthesis of Structural Proteins
 - Utilize the host Ribosome
 - Poor drug target
 - Some viruses utilize specific enzymes for protein maturation
 - Protease Drugs
 - HIV, Hepatitis C
- Assembly of Viral Particles & Release from Host Cell
 - Capsid proteins self-assemble
 - Nucleic acid inside
 - Viral proteins outside
 - Release may destroy cell
 - Lyric virus, herpes, influenza
 - Cell may remain intact
 - Papilloma, herpes
 - Only a few drug targets (HIV, Influenza)

Antiviral Drugs require Viral Enzyme Targets

- Enzyme should be structurally unrelated to host enzymes
 - Provides selectivity
- Most viral enzymes are involved in nucleic acid replication

Herpes

- Virus causes chronic recurrent infections
- Virus is able to escape immune system
 - Latency in neurons
- HSV-1
- HSV-2
 - Other subtypes less prevalent

HSV-1

- Cold sores and fever blisters on the mouth and nose, sometimes eye
- More than 80% of the population is infected
- Only 10-20% experience outbreaks

- Virus escapes eradication by latency inside neurons
 - Inaccessible to immune system
 - Stress, sunlight, immune suppression trigger outbreaks
 - Virus travels down axon to epithelial cells
- Lytic Infection
 - Only in epithelial cells, does not damage neurons
- Outbreaks
 - Lytic infection
 - Viral activity is short (less than 24 hours)
 - Viral damage is minimal
 - Most damage is caused by the immune system
 - Over stimulated and destroys most of the tissue
 - Drug must be administered quickly

HSV-2

- Sores and fever blisters on the anus and genitals
- Infects 15-20% of population
- Infection is much more violent than HSV-1
- Usually one outbreak per year
- Most common type of STD
- Viral activity is short
 - Viral damage is minimal
- Most damage by immune system
 - Drug must be administered quickly

Herpes Virus Structure

- Genetic Information is double stranded DNA
- Very complex virus
 - More than 70 genes
 - Most viruses have less than 10
- Virus has its own polymerase
 - Enzyme that can make nucleic acid

Components of Nucleic Acid

- Nucleosides (no phosphate)
- Sugar (2-deoxyribose on DNA or ribose in RNA)
- Base - nitrogen containing aromatic heterocycle
 - Heterocycles are ring structures incorporating heteroatoms

Base Form a Type of Alphabet

- Four different bases (ACTG)
- Each base is "recognized" by other molecules because of its shape and hydrogen bonding pattern
- Enables binding of only certain structures to each base

Structure of Nucleic Acids

- Polymers formed by connecting nucleosides together using phosphate esters
- The individual units are now called nucleotides (phosphate containing)

- Forms a long strand
- Backbone of sugars and phosphates
- One base per sugar
- Bound in antiparallel direction
 - Stabilizes structure

Nucleic Acid Strand

- Nucleic acid encodes information in its structure
- Info is stored as the sequence of bases
- Polymerases use one strand as a template to make another strand


Nucleic Acids can form Double Strands

- Stabilize the molecules
 - Long-term storage
- Second strand provides an easy way to replicate or read information
- Error checking

Polymerases copy Nucleic Acids

- Use one strand as a template to make another strand
- Nucleotides are added one at a time, matching each added base against its complement on the other strand

Polymerase creates new Strand



Polymerase adds Bases One-at-a-time

- After each base is added, a new 3' OH nucleophile is available for next addition

Rational Drug Design

- Use knowledge of enzyme mechanism and substrate to design a drug

Selectivity Problem with Nucleic Acids

- Must block viral enzyme without blocking host
- No chemical difference between viral nucleic acid and host nucleic acid
- Must find a drug that block viral polymerase but does not bother host polymerase

Poor Selectivity = Toxicity

- Interference with normal cell function creates problems
- Viral polymerase creates a viral nucleic acids which creates a viral protein

Strategy 1 - Non-Natural Base

- Resulting nucleic acid strand is non readable by host enzymes

Effects of Non-Natural Base

- Substrate structure disrupted, polymerase cannot function
- Nucleic acid not readable by other enzymes

Requirements for Non-Natural Base

- Drug is a substrate for kinase
 - Host
 - Virus (rare)
- Drug is a substrate for viral polymerase
 - Gets incorporated into viral nucleic acid
 - Creates an “unreadable” strand
- Drug must NOT be a substrate for host polymerase
 - Will cause side effects

Selectivity Requirements for Non-Natural Base

-